{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urinary-tract-infection-children/management/uti-in-children/","result":{"pageContext":{"chapter":{"id":"732454b5-6086-54ad-8fe0-68d4d8c9b5f8","slug":"uti-in-children","fullItemName":"Scenario: UTI in children","depth":2,"htmlHeader":"<!-- begin field 4aa7e142-67be-43a7-8eb8-588704439156 --><h2>Scenario: Urinary tract infection in children</h2><!-- end field 4aa7e142-67be-43a7-8eb8-588704439156 -->","summary":"Covers the management of children with a urinary tract infection.","htmlStringContent":"<!-- begin item c53430dc-2cc1-420b-8860-ae87973ff872 --><!-- begin field d2be1d91-ead0-40d1-8169-acbc015a7361 --><p>From birth to 16 years.</p><!-- end field d2be1d91-ead0-40d1-8169-acbc015a7361 --><!-- end item c53430dc-2cc1-420b-8860-ae87973ff872 -->","topic":{"id":"991f627d-8926-57b4-aaf8-67af4fd5db9d","topicId":"510a3aa0-27ac-462a-a52b-fe6491d08ab0","topicName":"Urinary tract infection - children","slug":"urinary-tract-infection-children","lastRevised":"Last revised in February 2019","chapters":[{"id":"d1ecfd05-b7d6-5f26-958b-08cbc3d78492","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5867e1c1-3817-541e-8b04-bef811c2f6c4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"79d4f794-da69-53db-a658-5ce7c959f692","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2f77533f-9993-5dbe-aec4-d0ee486a2559","slug":"changes","fullItemName":"Changes"},{"id":"79054143-84a5-50b1-8bcd-34d7ea4ff7da","slug":"update","fullItemName":"Update"}]},{"id":"26055421-3310-5e60-9152-68faccc1b450","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2e0770ba-47ca-5e33-8ed4-cc1f3f27b080","slug":"goals","fullItemName":"Goals"},{"id":"9b22c988-34f6-555d-9dc3-8ab3bb093e3a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fe1b7a61-e520-56e2-be30-8608881cdb7f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2b6a45d0-fdcd-5821-864d-63a74db81d6a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6f051e1-15a3-55a3-be65-2a623b2dae1c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8b4bab45-57e8-59b8-bd66-9036dc2fc571","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"dd9ffb6c-bd87-54d5-8c87-1e080e01ea4b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"1136e250-9882-5b2e-a75c-91e52993494f","slug":"definition","fullItemName":"Definition"},{"id":"45b0687c-19a3-5dc0-a5aa-e56c1e8d1061","slug":"causal-organisms","fullItemName":"Causal organisms"},{"id":"003daae9-bb06-5297-8ac5-cabcf10e7968","slug":"prevalence","fullItemName":"Prevalence"},{"id":"750a5b3e-7655-5653-bd66-cbf33a4daffe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"2d85acf8-d02b-5815-bb49-4c5f17b8678f","slug":"prognosis","fullItemName":"Prognosis"},{"id":"9f9d006d-bcda-5469-81d7-d2c3123c99d4","slug":"complications","fullItemName":"Complications"}]},{"id":"0bd6000e-bd4c-5f90-a711-bd23da73865d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8f91b779-7c82-5647-b2f7-d8c90726d303","slug":"suspecting-a-urinary-tract-infection","fullItemName":"Suspecting a urinary tract infection"},{"id":"5e82d0e6-4bfb-58c7-955f-7d2bc44d7ff6","slug":"diagnosing-a-urinary-tract-infection","fullItemName":"Diagnosing a urinary tract infection"},{"id":"57282b06-7213-5787-8603-4673c4ead4c4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d3a08393-35d5-53dc-935a-d5e32abee30b","fullItemName":"Management","slug":"management","subChapters":[{"id":"732454b5-6086-54ad-8fe0-68d4d8c9b5f8","slug":"uti-in-children","fullItemName":"Scenario: UTI in children"},{"id":"47d251fa-94da-5df5-889b-aec47b266935","slug":"recurrent-uti-in-children","fullItemName":"Scenario: Recurrent UTI in children"}]},{"id":"fcc5959a-b3b9-5135-9a34-0567f5ec597e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"49e814b6-1bc7-5c87-91e7-ea6edc49413f","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"178d0dc1-f68e-5c02-8ab6-590182cdb89b","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin"},{"id":"f0eecb36-6697-52c3-ba61-43722573d661","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"32a374c4-43e1-56a3-bc3a-3750191e085c","slug":"amoxicillin","fullItemName":"Amoxicillin"}]},{"id":"8b665f09-70b4-5fb0-a6c8-77c4766fc268","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1d405e7c-5e75-5615-8deb-94bb5f1d64cb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"82284d2f-4c04-573e-861c-5f030553a063","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"27e92d92-08e0-5fd8-aa0b-a5d456171c04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3afd108c-e35b-5034-9573-81cf33f52df5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ce068350-baea-5cb3-9040-ab2a90e020f8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e6c46138-9934-5c77-9727-4d36f784738d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"46eac86e-96b0-524a-ac9a-887b17be1e1c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d3a08393-35d5-53dc-935a-d5e32abee30b","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"04a0a236-0bc8-559b-b568-81d51d28d667","slug":"managing-urinary-tract-infection","fullItemName":"Managing urinary tract infection","depth":3,"htmlHeader":"<!-- begin field 96e701c3-0a32-4f6f-b76b-a560d48b9d74 --><h3>How should I manage urinary tract infection in an infant or child?</h3><!-- end field 96e701c3-0a32-4f6f-b76b-a560d48b9d74 -->","summary":null,"htmlStringContent":"<!-- begin item 7524fb8a-5ae9-4687-9f23-24ce820d3b78 --><!-- begin field 4926b3d6-d87b-4252-b4b0-cab40a9906b7 --><ul><li><strong>If the child has been assessed at high <a class=\"topic-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/diagnosis/diagnosing-a-urinary-tract-infection/#risk-of-serious-illness\">risk of serious illness</a>, refer urgently to secondary care.</strong></li><li><strong>If UTI is suspected in children aged under 3 months — refer urgently to a paediatric specialist for treatment with parenteral antibiotics, and send a urine sample for urgent microscopy and culture. </strong></li><li><strong>For children 3 months or older with acute pyelonephritis/upper UTI: </strong><ul><li>Consider referral to a paediatric specialist. Use clinical judgement to determine whether this is necessary.</li><li>Start oral antibiotic treatment with cefalexin, or co-amoxiclav (only if culture results are available and susceptible).<ul><li>If culture results show that the causative organism is resistant to the initially prescribed antibiotic, switch to an alternative.</li><li>Infants and children who are already receiving prophylactic antibiotics, should be treated with an alternative antibiotic.</li></ul></li><li>Prescribe cefalexin at the following doses, for children aged: <ul><li>3–11 months — 12.5 mg/kg or 125 mg twice a day for 7–10 days (25 mg/kg two to four times a day [maximum 1 g four times a day] for severe infections).</li><li>1–4 years — 12.5 mg/kg twice a day or 125 mg three times a day for 7–10 days (25 mg/kg two to four times a day [maximum 1 g four times a day] for severe infections).</li><li>5 –11 years — 12.5 mg/kg twice a day or 250 mg three times a day for 7–10 days (25 mg/kg two to four times a day [maximum 1 g four times a day] for severe infections).</li><li>12–15 years — 500 mg two to three times a day (up to 1–1.5 g three to four times a day for severe infections) for 7–10 days.</li></ul></li><li>Prescribe co-amoxiclav at the following doses, for children aged: <ul><li>3 –11 months — 0.25 mL/kg of 125/31 suspension three times a day for 7–10 days (dose doubled in severe infection).</li><li>1–5 years — 0.25 mL/kg of 125/31 suspension or 5 ml of 125/ 31 suspension three times a day for 7–10 days (dose doubled in severe infection).</li><li>6 –11 years — 0.15 mL/kg of 250/62 suspension or 5 ml of 250/ 62 suspension three times a day for 7–10 days (dose doubled in severe infection).</li><li>12–15 years — 250/125 mg or 500/125 mg three times a day for 7–10 days.</li></ul></li></ul></li><li><strong>For all children 3 months or older with cystitis/lower UTI: </strong><ul><li>Start oral antibiotic treatment — first line options include trimethoprim (if there is low risk of resistance), or nitrofurantoin (if eGFR ≥ 45ml/minute). Second line options include nitrofurantoin (if eGFR ≥ 45ml/minute) if it has not been used as a first-line option, amoxicillin (only if culture results available and susceptible), or cefalexin.<ul><li>If culture results show that the causative organism is resistant to the initially prescribed antibiotic, switch to an alternative.</li><li>Infants and children who are already receiving prophylactic antibiotics, should be treated with an alternative antibiotic.</li></ul></li><li>Prescribe trimethoprim at the following doses, for children aged:<ul><li>3–5 months — 4 mg/kg (maximum 200 mg per dose) or 25 mg twice a day for 3 days.</li><li>6 months to 5 years — 4 mg/kg (maximum 200 mg per dose) or 50 mg twice a day for 3 days.</li><li>6 –11 years — 4 mg/kg (maximum 200 mg per dose) or 100 mg twice a day for 3 days.</li><li>12–15 years — 200 mg twice a day for 3 days.</li></ul></li><li>Prescribe nitrofurantoin at the following doses, for children aged: <ul><li>3 months to 11 years — 750 micrograms/kg four times a day for 3 days.</li><li>12 –15 years — 50 mg four times a day or 100 mg modified-release twice a day for 3 days.</li></ul></li><li>Prescribe amoxicillin at the following doses, for children aged: <ul><li>1–11 months — 125 mg three times a day for 3 days</li><li>1–4 years — 250 mg three times a day for 3 days.</li><li>5–15 years — 500 mg three times a day for 3 days.</li></ul></li><li>Prescribe cefalexin at the following doses, for children aged:<ul><li>3–11 months — 12.5 mg/kg or 125 mg twice a day for 3 days.</li><li>1–4 years — 12.5 mg/kg twice a day or 125 mg three times a day for 3 days.</li><li>5–11 years — 12.5 mg/kg twice a day or 250 mg three times a day for 3 days.</li><li>12–15 years — 500 mg twice a day for 3 days.</li></ul></li></ul></li><li><strong>Arrange ultrasound of the urinary tract:</strong><ul><li><strong>During the acute infection in all children with atypical infection, indicated by: </strong><ul><li>Poor urine flow.</li><li>Abdominal or bladder mass.</li><li>Raised creatinine.</li><li>Sepsis.</li><li>Failure to respond to treatment with suitable antibiotics within 48 hours.</li><li>Infection with non-<em>E. coli</em> organisms.</li><li>Note: infants and children with abnormal imaging results should be assessed by a paediatric specialist.</li></ul></li><li><strong>During the acute infection in children aged under 6 months with <a class=\"topic-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/management/recurrent-uti-in-children/#managing-recurrent-uti-in-children\">recurrent UTI</a>.</strong></li><li><strong>Within 6 weeks for children aged 6 months and over with  <a class=\"topic-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/management/recurrent-uti-in-children/#managing-recurrent-uti-in-children\">recurrent UTI</a>.</strong></li><li><strong>Within 6 weeks, for all children younger than 6 months of age with first-time UTI that responds to treatment.</strong></li></ul></li><li><strong>Ensure that a dimercaptosuccinic acid scintigraphy (DMSA) scan to detect renal parenchymal defects is carried out within 4–6 months following the acute infection in:</strong><ul><li>All children aged under 3 years with atypical or <a class=\"topic-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/management/recurrent-uti-in-children/#managing-recurrent-uti-in-children\">recurrent UTI</a>. </li><li>All children aged 3 years or over with <a class=\"topic-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/management/recurrent-uti-in-children/#managing-recurrent-uti-in-children\">recurrent UTI</a>.  </li><li>This investigation should be arranged by paediatric specialists when appropriate. </li></ul></li><li><strong>If dysfunctional elimination syndromes and/or constipation are suspected, these should be addressed. </strong><ul><li>For children with suspected voiding dysfunction and/or urine withholding, regular bladder-emptying during the day (every 90–120 minutes) should be advised. </li><li>Stool softener may be prescribed if there is constipation. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/constipation-in-children/\">Constipation in children</a>. </li></ul></li><li><strong>Ensure that all children with UTI with an antenatally diagnosed renal abnormality and/or hypertension have received follow-up with a paediatric nephrologist. </strong><ul><li>Use clinical judgement to determine whether those with a family history of vesicoureteric reflux or renal disease require secondary care follow-up.</li></ul></li><li><strong>Provide parents or carers with information and advice.</strong><ul><li>Advise the parents or carers to bring the child for reassessment if they do not respond to treatment within 24–48 hours. <ul><li>At this follow-up, if an alternative diagnosis is not made, a urine sample should be sent for culture if this has not already been carried out. </li></ul></li><li>Outline the importance of completing any course of treatment.</li><li>Advise use of paracetamol for pain relief where required. For information on prescribing, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/\">Paracetamol</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>. </li><li>Advise on adequate fluid intake to avoid dehydration. </li><li>Advise that children who have had a UTI should have ready access to clean toilets when required and should not be expected to delay voiding. </li><li>Ensure that they are aware of the possibility of a UTI recurring and the need to seek prompt treatment from a healthcare professional should this occur. </li><li>Patient information leaflets on UTI in children are available at <a href=\"https://www.nhs.uk/conditions/urinary-tract-infections-utis-in-children/\" data-hyperlink-id=\"a98dc81c-1a39-4390-a85f-a9930006367c\">NHS</a> and <a href=\"https://patient.info/doctor/urinary-tract-infection-in-children\" data-hyperlink-id=\"523f36e7-2870-491e-aa55-a9930006368a\">Patient.Info</a>.</li></ul></li></ul><!-- end field 4926b3d6-d87b-4252-b4b0-cab40a9906b7 --><!-- end item 7524fb8a-5ae9-4687-9f23-24ce820d3b78 -->","subChapters":[{"id":"c4637cc8-ab00-5fcb-aeb8-3bb21faa8b2f","slug":"basis-for-recommendation-5ce","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3c108fee-329d-4638-b036-fef139dd5e76 --><h4>Basis for recommendation</h4><!-- end field 3c108fee-329d-4638-b036-fef139dd5e76 -->","summary":null,"htmlStringContent":"<!-- begin item 5ce3623c-a804-4d98-9cc3-5a43808aebb2 --><!-- begin field cb3af7d5-97e7-41be-9762-8ede238e9600 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Urinary tract infection in children: diagnosis, treatment and long-term management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">NICE, 2018a</a>], <em>Urinary tract infection (lower): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">NICE, 2018b</a>], <em>Pyelonephritis (acute): antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">NICE, 2018c</a>], <em>Fever in under 5s: assessment and initial management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">NICE, 2017a</a>], and the British Medical Journal (BMJ) best practice guide <em>Urinary tract infections in children</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">BMJ, 2018</a>]. </p><h5>Specialist follow-up for children with UTI with an antenatally diagnosed renal abnormality, high blood pressure, or with a family history of vesicoureteric reflux or renal disease</h5><ul><li>The advice to ensure that infants/children with UTI with an antenatally diagnosed renal abnormality and/or high blood pressure have been followed-up in secondary care is extrapolated from the NICE guideline <em>Urinary tract infection in children: diagnosis, treatment and long-term management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">NICE, 2018a</a>], which states that infants and children who have bilateral renal abnormalities, impaired kidney function, raised blood pressure and/or proteinuria should receive monitoring and appropriate management by a paediatric nephrologist to slow the progression of chronic kidney disease. In practice, it is likely that individuals with such an antenatal diagnosis will have been followed-up after birth where necessary, but the recommendation to ensure that this has occurred is pragmatic, based on what CKS considers to be good medical practice.</li><li>The advice to consider secondary care follow-up for those with UTI and a family history of vesicoureteric reflux or renal disease is also based on the NICE guideline <em>Urinary tract infection in children: diagnosis, treatment and long-term management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">NICE, 2018a</a>], which states that these are risk factors for serious underlying pathology in UTI. The pragmatic advice to consider specialist referral if these factors are present is based on what CKS considers to be good medical practice, and will likely depend on a number of factors such as whether UTI is complicated or recurrent, whether the upper or lower urinary tract is affected, and the age of the child (for example, referral may not be considered necessary following initial presentation of UTI in an older child).</li></ul><!-- end field cb3af7d5-97e7-41be-9762-8ede238e9600 --><!-- end item 5ce3623c-a804-4d98-9cc3-5a43808aebb2 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}